|
Randomized, Placebo-Controlled Study of Ethyl-Eicosapentaenoic Acidas Supplemental Treatment in Schizophrenia Robin Emsley, M.D.Christo Myburgh, M.B.Pieter Oosthuizen, M.B.Susan J. van Rensburg, Ph.D. Objective: The study investigated the efficacy and tolerability of ethyl-eicosapentaenoic acid (E-EPA) as add-on treatment in chronic, severe schizophrenia. Method: A randomized, parallel-group, double-blind, placebocontrolled, fixed-dose, add-on study was conducted over 12 weeks. Forty patients with persistent symptoms after at least 6 months of stable antipsychotic treatment received E-EPA or placebo, in addition to their existing treatment. Results: At 12 weeks, the E-EPA group had significantly greater reduction of Positive and Negative Syndrome Scale total scores and of dyskinesia scores than the placebo group. Conclusions: EPA may be an effective and well-tolerated addon treatment in schizophrenia. (Am J Psychiatry 2002; 159:1596–1598) For Full Report Click your mouse on this text
|
©